Current Essentials in Inflammatory Myopathies - European Medical Journal

Current Essentials in Inflammatory Myopathies

Download PDF
Maren Breithaupt,1 Jens Schmidt1,2

JS has received payments for consultancies or talks, or honoraria, or reimbursements for
travel, or research grants from Bayer, Biotest, CSL Behring, Novartis, and Octapharma.

EMJ Neurol. ;1[1]:46-51. DOI/10.33590/emjneurol/10311206.
Myositis, muscle inflammation, polymyositis, dermatomyositis, necrotising myopathy, inclusion body myositis

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Inflammatory myopathies are a heterogeneous group of acquired systemic diseases, which include dermatomyositis (DM), polymyositis (PM), necrotising myopathy (NM) and inclusion body myositis (IBM). All four disease entities share certain clinical characteristics, such as progressive muscle weakness and elevated muscle enzymes. Other characteristic-associated features such as skin involvement in DM or the detection of myositis-specific antibodies, may be indicative of a particular subtype. However, muscle biopsy is still essential for the diagnosis and shows distinct histopathological characteristics for each subtype of myositis. Treatment of inflammatory myopathies is still based on clinical experience, since placebo-controlled trials are scarce. While DM, PM and NM respond well to immunosuppressive treatment, IBM is usually resistant to immunotherapy. This review aims to give a concise overview and provide guidance for general management of myositis.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?